Effectiveness of venous thromboembolism prophylaxis in patients with liver disease

Table 1 Baseline characteristics

	No prophylaxis(n = 903)	Prophylaxis(n = 903)
Mean age (yr)	60.1 ± 11.9	60.2 ± 11.8
Male	572 (63.3)	535 (59.2)
RRTa	221 (24.5)	267 (29.6)
CKD	226 (25.0)	238 (26.4)
Lung disease	218 (24.1)	218 (24.1)
Heart failure	192 (21.3)	196 (21.7)
MVP	291 (32.2)	286 (31.7)
VTE risk scorec
Unknown risk score	103 (11.4)	78 (8.6)
Low risk	26 (2.9)	17 (1.9)
Medium risk	591 (65.4)	680 (75.3)
High risk	183 (20.3)	128 (14.2)
BMI (kg/m2)	24.4 ± 0.20	24.4 ± 0.20
INRc	1.4 ± 0.57	1.3 ± 0.32
Platelet count (k/µL)	144.2 ± 92.5	151.0 ± 97.0
aPTT (s)	34.8 ± 12.0	34.4 ± 10.2
Albumin (g/dL)	2.9 ± 0.70	2.9 ± 0.67
Tbili (mg/dL)	4.0 ± 7.1	3.8 ± 6.6
SCr (mg/dL)	1.5 ± 1.3 a	1.6 ± 1.5
Hemoglobin (g/dL)	10.4 ± 2.3 b	10.7 ± 2.1
Liver disease etiology
Alcoholic	278 (30.8)	286 (31.7)
NASH	27 (3.0)	22 (2.4)
Acute Hepatitis	35 (3.9)	38 (4.2)
Other1	563 (62.3)	557 (61.7)
Mean MELD score	17.0 ± 9.1	17.4 ± 8.3
MELD categoryc
MELD > 40	20 (2.2)	8 (0.89)
MELD 30-39.9	71 (7.9)	74 (8.2)
MELD 20-29.9	205 (22.7)	233 (25.8)
MELD 10-19.9	338 (37.4)	386 (42.7)
MELD < 10	269 (29.8)	202 (22.4)

Data presented as n (%) or mean ± SD.

¹Other liver disease includes primary sclerosing cholangitis, biliary cirrhosis, cirrhosis due to alpha-1 antitrypsin deficiency, and any other liver disease not included above. This categorization is for the primary hepatic International Classification of Diseases, 9^th edition (ICD-9) code for an admission; all patients had an ICD-9 code for cirrhosis.

^aP < 0.05 vs prophylaxis group;

^bP < 0.01 vs prophylaxis group;

^cP < 0.001 vs prophylaxis group. RRT: Renal replacement therapy; CKD: Chronic kidney disease; MVP: Mechanical venous thromboembolism prophylaxis; BMI: Body mass index; INR: International normalized ratio; aPTT: Activated partial thromboplastin time; Tbili: Total bilirubin; SCr: Serum creatinine; NASH: Non-alcoholic steatohepatitis; MELD: Model for end-stage liver disease.